RGCRegencell Bioscience Holdings Limited
What is the market doing?
No clear lean: rangebound and a token position.
Rangebound, no clear trend. Overbought (RSI 73). Price is −63% vs its 200-day average.
A token position, settled Sep 15, 2026, about a week of normal trading to cover. Down 16% since the previous count, unchanged over three months.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RGC is trading
Regencell Bioscience Holdings Limited is −53% over the past year while the S&P 500 is +18%: 72 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −63%
vs 200-day average · a clear downtrend
- RSI (14)
- 73
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 86%
Below its 52-week high
Details›
- Last close2026-10-09
- $7.30
- 1 monthS&P 500 +2.7%
- +30%
- 1 yearS&P 500 +18%
- −53%
- 5 yearsS&P 500 +88%
- +1033%
- vs 50-day average$5.96
- +23%
- 52-week high
- $52.88
- 52-week low
- $4.75
- Annualised volatility
- 337%
| Year | Return |
|---|---|
| 2026 (year to date) | −65% |
| 2025 | +16054% |
| 2024 | −53% |
| 2023 | −62% |
| 2022 | −12% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | −3.1% |
| Feb | 5 | 3 of 5 | +2.2% |
| Mar | 5 | 1 of 5 | +102% |
| Apr | 5 | 5 of 5 | +26% |
| May | 5 | 2 of 5 | +270% |
| Jun | 5 | 2 of 5 | −20% |
| Jul | 5 | 1 of 5 | +24% |
| Aug | 6 | 2 of 6 | +39% |
| Sep | 6 | 3 of 6 | −7.5% |
| Oct | 6 | 4 of 6 | +0.36% |
| Nov | 5 | 2 of 5 | +6.7% |
| Dec | 5 | 2 of 5 | +15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #40 of 41 by RyuScore